Aastrom Biosciences

Latest Headlines

Latest Headlines

Aastrom surges after acquiring Sanofi's cell therapies

A little more than a year after reorganizing the company and slashing staff in the wake of a Phase III failure, Ann Arbor, MI-based Aastrom Biosciences has acquired Sanofi's cell therapy and regenerative medicine business for the low, low purchase price of $6.5 million--$4 million payable in cash and $2.5 million in a promissory note.

Aastrom lands a new CEO in a game of musical biotech chairs

Shares of Aastrom bounced higher yesterday as biotech veteran Dominick Colangelo was named the new CEO, taking the reins during a crucial pivotal study of the company's personalized cell therapy.

Aastrom banks $38M for pivotal study of cellular therapy

Aastrom Biosciences' ($ASTM) stock was up this morning after the developer announced a $40 million financing deal with Eastern Capital.

Aastrom puts hopes in promising CLI therapy

Xconomy's Luke Timmerman profiles Ann Arbor, MI-based Aastrom Biosciences, which is planning to enroll 500-600 patients with critical limb ischemia to test a promising treatment approach. Its

Court lifts ban on stem cell funding during appeal

The U.S. Court of Appeals in Washington has temporarily stayed a cut-off in government funding for human embryonic stem cell research. As a result of the stay, the Obama administration can fund

Which biotechs are the least efficient?

SmartTrend has looked at the biotech industry to determine which companies are the least efficient. Using revenue per employee (RPE)--a ratio useful when comparing a company against others in its

Aastrom shares jump as FDA lifts clinical hold

Aastrom's shares are up on the news that the FDA has lifted a clinical hold on the company's Phase II congestive heart failure trial. The trial is testing cardiac repair cells (CRC), which contain

Aastrom halts mid-stage trial after patient death

Aastrom Biosciences shares slid 24 percent Friday morning on the news that the company halted a mid-stage trial for a congestive heart failure treatment following the death of a patient. The Ann

Aastrom shares soar after FDA lifts hold

Aastrom Biosciences says that the FDA has removed the clinical hold from its U.S. Phase II IMPACT-DCM clinical trial for congestive heart failure and that patient enrollment would resume at the four

Aastrom stem cell therapy has high success rate

In a small stem cell study involving 33 patients, researchers for Aastrom Biosciences are reporting a 91 percent success rate in repairing hard-to-heal fractures. All of the patients in the study had